Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.

[1]  David C. Miller,et al.  Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. , 2018, European urology.

[2]  P. Kantoff,et al.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[4]  F. Montorsi,et al.  Impact of stage migration and practice changes on high‐risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades , 2016, BJU international.

[5]  F. Montorsi,et al.  Natural history of surgically treated high-risk prostate cancer. , 2015, Urologic oncology.

[6]  Hans Garmo,et al.  Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.

[7]  F. Montorsi,et al.  Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. , 2013, European urology.

[8]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[9]  F. Montorsi,et al.  Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. , 2012, European urology.

[10]  Rosalia Viterbo,et al.  Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer , 2011, Cancer.

[11]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[12]  M. Kattan,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[13]  M. Cooperberg,et al.  High-risk prostate cancer in the United States, 1990–2007 , 2008, World Journal of Urology.

[14]  M. Terris,et al.  Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10 , 2006, Cancer.

[15]  V. Coviello,et al.  Cumulative Incidence Estimation in the Presence of Competing Risks , 2004 .

[16]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.

[17]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[18]  F. Montorsi,et al.  Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. , 2015, European urology.

[19]  F. Montorsi,et al.  A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.